AbbVie Receives FDA Approval for Parkinson's Treatment Juvmo
The U.S. Food and Drug Administration (FDA) has approved AbbVie’s once-daily pill, Juvmo (tavapadon), as a treatment for adults with Parkinson’s disease. This marks the first FDA-approved therapy to selectively target D1/D5 dopamine receptors in the brain, offering doctors an additional tool to manage symptoms like stiffness and tremors. Juvmo is one of the key assets from AbbVie's $8.7 billion acquisition of Cerevel Therapeutics completed in 2024. While near-term revenue projections are modest—$8 million this year and $70 million next—the drug could reach annual sales of up to $1.4 billion by 2040, contributing to the expansion of AbbVie’s neuroscience portfolio. AbbVie is diversifying its growth strategy beyond Humira, which lost U.S. patent exclusivity, with a focus on neuroscience and other therapeutic areas like immunology and oncology.
Tickers: $ABBV